Tuesday, Oct 20, 2020 | Last Update : 06:11 PM IST

195th Day Of Lockdown

Maharashtra1443409114960338084 Andhra Pradesh7192566588755981 Karnataka6406615157829286 Tamil Nadu6088555529389653 Uttar Pradesh4031013468595864 Delhi2827522506135401 West Bengal2603242287555017 Odisha222734190080912 Kerala204242131048772 Telangana1992761701091163 Bihar178882164537888 Assam169985139977655 Gujarat1332191132403417 Rajasthan1288591077181441 Haryana1237821059901307 Madhya Pradesh117588932382207 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  World   Americas  27 Jul 2020  US doubles COVID vaccine fund as Moderna enters final phase of clinical trial

US doubles COVID vaccine fund as Moderna enters final phase of clinical trial

AFP
Published : Jul 27, 2020, 2:02 pm IST
Updated : Jul 27, 2020, 2:02 pm IST

US has announced massive investments to speed up vaccine development and get millions of Americans vaccinated by early next year

 With laboratories around the world in a furious race to develop a first effective vaccine, Moderna seems to hold the lead as it enters a final round of clinical trials -- a decisive step in determining whether a vaccine is both effective and safe. (AFP)
  With laboratories around the world in a furious race to develop a first effective vaccine, Moderna seems to hold the lead as it enters a final round of clinical trials -- a decisive step in determining whether a vaccine is both effective and safe. (AFP)

Washington: The United States has doubled its investment -- to nearly $1 billion -- to expedite development of a potential COVID-19 vaccine by American firm Moderna, which on Monday begins the decisive final phase of clinical trials.

The government now plans to spend up to $472 million on top of the previously announced $483 million, the Moderna biotechnology company announced Sunday.

 

Moderna said the added investment was justified by its decision, in conjunction with the government, to "significantly" expand a Phase Three clinical trial of a candidate vaccine to include 30,000 participants.

In a small, initial trial, Moderna's experimental vaccine produced coronavirus antibodies -- which should help fend off the disease -- in the bodies of all 45 participants.

In the expanded trial starting Monday, half the 30,000 participants will receive a 100-microgram dose of the vaccine, while the rest will be given a placebo.

The United States has suffered more than 146,000 coronavirus deaths, leading the world in that grim category, even as the number of new cases has continued to surge.

 

It has announced massive investments in a huge effort to expedite vaccine development and get millions of Americans vaccinated by early next year.

On Wednesday, the American-German BioNTech/Pfizer pharmaceutical alliance announced that the US government had committed $1.95 billion to procure 100 million doses of its eventual vaccine.

With laboratories around the world in a furious race to develop a first effective vaccine, Moderna seems to hold the lead as it enters a final round of clinical trials -- a decisive step in determining whether a vaccine is both effective and safe.

Moderna, which has been working with US health authorities, said it expects to be able to produce 500 million doses a year -- and potentially up to 1 billion -- starting in 2021.

 

Chinese biotech firm Sinovac said July 6 that it, too, would begin a Phase Three clinical trial "this month," in collaboration with Brazil's Butantan biologic research center.

Also reporting encouraging early results have been a British project developed by Oxford University in partnership with the multinational AstraZenica laboratory, and a Chinese project, led by researchers from agencies including the Academy of Military Medical Sciences.

That effort is being financed by the CanSino biotechnology group, which is listed on the Hong Kong stock exchange.

In all, nearly 200 candidate vaccines are in development, including 23 now in the clinical phase, being tested on humans.

 

Tags: coronavirus vaccine status, us coronavirus fund, moderna vaccine, cansino vaccine, astrazenica, oxford university vaccine, coronavirus vaccines, covid-19 vaccines, sinovac